Michael G. Chaparian
Keine laufenden Positionen mehr
Profil
Michael G.
Chaparian was the founder of SelectX Pharmaceuticals, Inc. founded in 2002, where he held the title of Chief Executive & Scientific Officer from 2010 to 2011.
He also held former positions as Director-Biotechnology Development at Arizona State University, President & Chief Scientific Officer at OmniScience Pharmaceuticals, Inc., and President at Blue Planet Technologies.
Dr. Chaparian received a doctorate degree from Wayne State University (Michigan) and an undergraduate degree from Michigan Technological University.
Ehemalige bekannte Positionen von Michael G. Chaparian
| Unternehmen | Position | Ende |
|---|---|---|
| Arizona State University | Corporate Officer/Principal | - |
| OmniScience Pharmaceuticals, Inc. | Präsident | - |
| Blue Planet Technologies | Präsident | - |
SelectX Pharmaceuticals, Inc.
 SelectX Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology SelectX Pharmaceuticals, Inc. engages in the discovery and development of aminoglycoside therapeutics for unmet medical needs. Its advanced program, development candidate SXP2523, is a next generation aminoglycoside antibiotic for drug resistant gram-negative hospital-acquired infections (HAIs); SXP2523 possesses broad spectrum coverage with potency against Pseudomonas, Klebsiella, Acinetobacter, E. coli, and Staphylococcus. The company was founded by Michael G. Chaparian and Charles R. Cantor in 2002 and is headquartered in Boston, MA. | Gründer | - |
Ausbildung von Michael G. Chaparian
| Wayne State University (Michigan) | Doctorate Degree |
| Michigan Technological University | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Private Unternehmen | 3 |
|---|---|
SelectX Pharmaceuticals, Inc.
SelectX Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology SelectX Pharmaceuticals, Inc. engages in the discovery and development of aminoglycoside therapeutics for unmet medical needs. Its advanced program, development candidate SXP2523, is a next generation aminoglycoside antibiotic for drug resistant gram-negative hospital-acquired infections (HAIs); SXP2523 possesses broad spectrum coverage with potency against Pseudomonas, Klebsiella, Acinetobacter, E. coli, and Staphylococcus. The company was founded by Michael G. Chaparian and Charles R. Cantor in 2002 and is headquartered in Boston, MA. | Health Technology |
| OmniScience Pharmaceuticals, Inc. | |
| Blue Planet Technologies |
